GEN Exclusives

More »

GEN Poll

More »
Dec 28, 2011

Biopharma M&As in 2012

The past few years have certainly gotten the biotech industry used to seeing multiple acquisition deals well over $1 billion, particularly among drug developers. While M&A activity was strong in 2011, the number of those huge blockbuster agreements seems to be lower. Sanofi came in at number 1 with its $20.1 billion buy of Genzyme—about half of the $41 billion that last year’s top-spender, Novartis, paid for Alcon. The top-five list for 2011 ends with Forest Laboratories’ $1.2 billion purchase of Clinical Data, while last year the fifth place went to Daiichi Sankyo when it bought Ranbaxy for $4.6 billion. Do you expect mega mergers to return in full force next year? What’s your forecast for M&A activity among biopharmaceutical companies for 2012?

Do you think M&A activity among drug developers in 2012 will surpass 2011?

Yes
 
  70.7%
No
 
  20.7%
Undecided
 
  8.6%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?